# A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection

> **NCT02651194** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 104 (actual)

## Conditions studied

- Chronic Hepatitis C Virus (HCV) Infection

## Interventions

- **DRUG:** ABT-493/ABT-530

## Key facts

- **NCT ID:** NCT02651194
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12
- **Primary completion:** 2016-10
- **Final completion:** 2017-01
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2017-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02651194

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02651194, "A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02651194. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*